556 related articles for article (PubMed ID: 27452466)
1. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
[TBL] [Abstract][Full Text] [Related]
3. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
[TBL] [Abstract][Full Text] [Related]
4. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of small cell lung cancer: Overview from studies on neuroendocrine differentiation regulated by ASCL1 and Notch signaling.
Ito T
Pathol Int; 2024 May; 74(5):239-251. PubMed ID: 38607250
[TBL] [Abstract][Full Text] [Related]
6.
Voigt E; Wallenburg M; Wollenzien H; Thompson E; Kumar K; Feiner J; McNally M; Friesen H; Mukherjee M; Afeworki Y; Kareta MS
Mol Cancer Res; 2021 Dec; 19(12):2015-2025. PubMed ID: 34593608
[TBL] [Abstract][Full Text] [Related]
7. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer.
Duplaquet L; Li Y; Booker MA; Xie Y; Olsen SN; Patel RA; Hong D; Hatton C; Denize T; Walton E; Laimon YN; Li R; Jiang Y; Bronson RT; Southard J; Li S; Signoretti S; Qiu X; Cejas P; Armstrong SA; Long HW; Tolstorukov MY; Haffner MC; Oser MG
Nat Cell Biol; 2023 Sep; 25(9):1346-1358. PubMed ID: 37591951
[TBL] [Abstract][Full Text] [Related]
8. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
[TBL] [Abstract][Full Text] [Related]
9. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
[TBL] [Abstract][Full Text] [Related]
10. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
[TBL] [Abstract][Full Text] [Related]
11. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
Eur Urol; 2024 Jun; 85(6):523-526. PubMed ID: 37380560
[TBL] [Abstract][Full Text] [Related]
12. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Gay CM; Stewart CA; Park EM; Diao L; Groves SM; Heeke S; Nabet BY; Fujimoto J; Solis LM; Lu W; Xi Y; Cardnell RJ; Wang Q; Fabbri G; Cargill KR; Vokes NI; Ramkumar K; Zhang B; Della Corte CM; Robson P; Swisher SG; Roth JA; Glisson BS; Shames DS; Wistuba II; Wang J; Quaranta V; Minna J; Heymach JV; Byers LA
Cancer Cell; 2021 Mar; 39(3):346-360.e7. PubMed ID: 33482121
[TBL] [Abstract][Full Text] [Related]
13. Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
Chen CC; Tran W; Song K; Sugimoto T; Obusan MB; Wang L; Sheu KM; Cheng D; Ta L; Varuzhanyan G; Huang A; Xu R; Zeng Y; Borujerdpur A; Bayley NA; Noguchi M; Mao Z; Morrissey C; Corey E; Nelson PS; Zhao Y; Huang J; Park JW; Witte ON; Graeber TG
Cancer Cell; 2023 Dec; 41(12):2066-2082.e9. PubMed ID: 37995683
[TBL] [Abstract][Full Text] [Related]
14. Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions.
Hiatt JB; Doebley AL; Arnold HU; Adil M; Sandborg H; Persse TW; Ko M; Wu F; Quintanal Villalonga A; Santana-Davila R; Eaton K; Dive C; Rudin CM; Thomas A; Houghton AM; Ha G; MacPherson D
Sci Adv; 2024 Apr; 10(15):eadk2082. PubMed ID: 38598634
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
Rudin CM; Poirier JT; Byers LA; Dive C; Dowlati A; George J; Heymach JV; Johnson JE; Lehman JM; MacPherson D; Massion PP; Minna JD; Oliver TG; Quaranta V; Sage J; Thomas RK; Vakoc CR; Gazdar AF
Nat Rev Cancer; 2019 May; 19(5):289-297. PubMed ID: 30926931
[TBL] [Abstract][Full Text] [Related]
16. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
[TBL] [Abstract][Full Text] [Related]
17. The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.
Pearsall SM; Humphrey S; Revill M; Morgan D; Frese KK; Galvin M; Kerr A; Carter M; Priest L; Blackhall F; Simpson KL; Dive C
J Thorac Oncol; 2020 Dec; 15(12):1836-1843. PubMed ID: 32721553
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
Park S; Hong TH; Hwang S; Heeke S; Gay CM; Kim J; Jung HA; Sun JM; Ahn JS; Ahn MJ; Cho JH; Choi YS; Kim J; Shim YM; Kim HK; Byers LA; Heymach JV; Choi YL; Lee SH; Park K
EBioMedicine; 2024 Apr; 102():105062. PubMed ID: 38492534
[TBL] [Abstract][Full Text] [Related]
19. ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers.
Martin-Vega A; Earnest S; Augustyn A; Wichaidit C; Gazdar A; Girard L; Peyton M; Kollipara RK; Minna JD; Johnson JE; Cobb MH
bioRxiv; 2023 Jun; ():. PubMed ID: 37398419
[TBL] [Abstract][Full Text] [Related]
20. Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.
Udyavar AR; Wooten DJ; Hoeksema M; Bansal M; Califano A; Estrada L; Schnell S; Irish JM; Massion PP; Quaranta V
Cancer Res; 2017 Mar; 77(5):1063-1074. PubMed ID: 27932399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
